statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright restated their buy rating on shares of GlycoMimetics (NASDAQ:GLYC - Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a...

GlycoMimetics (NASDAQ:GLYC) Given Buy Rating at HC Wainwright

GlycoMimetics, Inc. (NASDAQ:GLYC - Free Report) - HC Wainwright issued their FY2026 EPS estimates for shares of GlycoMimetics in a report issued on Wednesday, March 27th. HC Wainwright analyst E...

HC Wainwright Weighs in on GlycoMimetics, Inc.'s FY2026 Earnings (NASDAQ:GLYC)

This is a signal that GLYC's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

GlycoMimetics (GLYC, $3.02) Stochastic Oscillator left the overbought zone on March 28, 2024

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX Research Report), GlycoMimetics...

Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)

Q4 2023 GlycoMimetics Inc Earnings Call Transcript

GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript March 27, 2024
GlycoMimetics, Inc. isnt one of the 30 most popular stocks among hedge funds at the end of the third quarter...

GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript

GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its...

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GLYC Advances Clinical Programs Despite Reporting Expected LossesRelated Stocks: GLYC...

GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript...

GlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call Transcript

This is a Bullish indicator signaling GLYC's price could rise from here. Traders may explore going long the stock or buying call options...

GlycoMimetics (GLYC, $3.05) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 20, 2024

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Volume	343,346.00
52-Wk High	$3.53
52-Wk Low	$1.11

GLYC GlycoMimetics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals